Skip to main content
. 2018 Apr 11;11:121. doi: 10.3389/fnmol.2018.00121

FIGURE 1.

FIGURE 1

Experimental time line and effects of GLYX-13 on MK-801-induced hyperactivity in the open-field test (OFT). (A) Mice received daily administration of vehicle 1, MK-801 (0.5 mg/kg, i.p.), for 14 days. Vehicle 2, GLYX-13 (0.01, 0.5, and 1 mg/kg, i.v.), treatment began on the 7th day after the start of MK-801 administration and continued until the end of the treatment. Twenty-four hours after the last drug treatment animals completed the OFT, novel object recognition task (NORT), and prepulse inhibition (PPI) test between day 1 and day 4. Immediately after the PPI, the hippocampus was removed and processed to assess immunohistochemical changes in NR2B and DISC1 expression, and changes in protein expression by western blotting. (B,C) After 14 days of treatment with MK-801, hyperactivity was induced in mice and compared to the control (vehicle 1 and vehicle 2) groups. Horizontal locomotor activity was examined as the distance traveled (cm) in 30 min. The distances traveled in 5 min intervals (B) and the total distance traveled in 30 min (C) are shown. Data represent the mean ± SEM (n = 12 per group; ∗∗∗P < 0.001, versus the vehicle 1 + vehicle 2-treated group; #P < 0.05 and ###P < 0.001, versus the MK-801 + vehicle 2-treated group).